Plus Therapeutics presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium (186 Re) Obisbemeda in leptomeningeal disease (LM) at the 2024 San Antonio Breast Cancer Symposium on December 17, 2024. The presentation specifically focused on breast cancer patients.
A single intrathecal dose of Rhenium (186 Re) Obisbemeda delivered favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation. This indicates promising activity in this patient population.
Based on the promising data observed, the company intends to move forward rapidly into a breast cancer-focused expansion cohort. Both single-dose and multiple-dose expansion trials are planned for 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.